Home
/
Carisma Therapeutics Inc.
/
Financials
/
Quarterly
Carisma Therapeutics Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Carisma Therapeutics Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2019
Sep 30, 2019
$0
Nov 12, 2019
Q2
2019
Jun 30, 2019
$0
Aug 8, 2019
Q1
2019
Mar 31, 2019
$0
May 10, 2019
Q3
2019
Sep 30, 2018
$0
Nov 12, 2019
Q2
2019
Jun 30, 2018
$0
Aug 8, 2019
Q1
2018
Mar 31, 2018
$0
May 15, 2018
Q3
2018
Sep 30, 2017
$0
Nov 9, 2018
Q2
2018
Jun 30, 2017
$0
Aug 14, 2018
Q1
2017
Mar 31, 2017
$0
May 4, 2017
Q3
2016
Sep 30, 2016
$28.65M
Nov 14, 2016
Q2
2017
Jun 30, 2016
$277.0K
Aug 14, 2017
Q1
2017
Mar 31, 2016
$229.0K
May 4, 2017
Q3
2016
Sep 30, 2015
$67.0K
Nov 14, 2016
Q2
2016
Jun 30, 2015
$114.0K
Aug 12, 2016
Q1
2016
Mar 31, 2015
$244.0K
May 5, 2016
Q3
2015
Sep 30, 2014
$539.0K
Nov 4, 2015
Q2
2015
Jun 30, 2014
$761.0K
Aug 13, 2015
Q1
2015
Mar 31, 2014
$568.0K
Apr 30, 2015
Q3
2014
Sep 30, 2013
$622.0K
Nov 13, 2014
Q2
2014
Jun 30, 2013
$202.0K
Aug 13, 2014
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$45.30M
Nov 12, 2025
Q2
2025
Jun 30, 2025
$3.70M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$3.70M
May 13, 2025
Q3
2025
Sep 30, 2024
$3.40M
Nov 12, 2025
Q2
2024
Jun 30, 2024
$9.20M
Aug 8, 2024
Q1
2025
Mar 31, 2024
$3.40M
May 13, 2025
Q3
2024
Sep 30, 2023
$3.80M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$3.60M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$3.20M
May 9, 2024
Q3
2023
Sep 30, 2022
$2.58M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$2.70M
Aug 10, 2023
Q1
2023
Mar 31, 2022
$822.0K
May 11, 2023
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$0
May 15, 2018
Q3
2017
Sep 30, 2017
$0
Nov 17, 2017
Q2
2017
Jun 30, 2017
$0
Aug 14, 2017
Q1
2018
Mar 31, 2017
$425.0K
May 15, 2018
Q3
2017
Sep 30, 2016
$28.65M
Nov 17, 2017
Q2
2017
Jun 30, 2016
$277.0K
Aug 14, 2017
Q1
2017
Mar 31, 2016
$229.0K
May 4, 2017
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$44.72M
Nov 12, 2025
Q2
2025
Jun 30, 2025
($9.77M)
Aug 7, 2025
Q3
2025
Jun 30, 2025
($9.77M)
Nov 12, 2025
Q2
2025
Mar 31, 2025
($9.27M)
Aug 7, 2025
Q3
2025
Mar 31, 2025
($9.27M)
Nov 12, 2025
Q1
2025
Mar 31, 2025
($9.27M)
May 13, 2025
Q3
2025
Sep 30, 2024
($12.70M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($11.16M)
Aug 7, 2025
Q3
2025
Jun 30, 2024
($11.16M)
Nov 12, 2025
Q1
2025
Mar 31, 2024
($18.98M)
May 13, 2025
Q2
2025
Mar 31, 2024
($18.98M)
Aug 7, 2025
Q3
2025
Mar 31, 2024
($18.98M)
Nov 12, 2025
Q3
2024
Sep 30, 2023
($21.40M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($19.88M)
Aug 8, 2024
Q3
2024
Jun 30, 2023
($19.88M)
Nov 7, 2024
Q3
2024
Mar 31, 2023
($24.64M)
Nov 7, 2024
Q1
2024
Mar 31, 2023
($24.64M)
May 9, 2024
Q3
2023
Sep 30, 2022
($18.33M)
Nov 9, 2023
Q3
2022
Jun 30, 2022
($31.96M)
Nov 7, 2022
Q2
2023
Jun 30, 2022
($14.85M)
Aug 10, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$43.81M
Nov 12, 2025
Q2
2025
Jun 30, 2025
($5.78M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($9.33M)
May 13, 2025
Q3
2025
Sep 30, 2024
($13.14M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($11.67M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($19.51M)
May 13, 2025
Q3
2024
Sep 30, 2023
($22.34M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($20.97M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($22.97M)
May 9, 2024
Q3
2023
Sep 30, 2022
($16.75M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($13.93M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($10.16M)
May 11, 2023
Q3
2022
Sep 30, 2021
$63.11M
Nov 7, 2022
Q2
2022
Jun 30, 2021
($25.40M)
Aug 25, 2022
Q1
2022
Mar 31, 2021
($55.22M)
May 9, 2022
Q3
2021
Sep 30, 2020
($21.48M)
Nov 8, 2021
Q2
2021
Jun 30, 2020
($26.36M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
$41.39M
May 10, 2021
Q3
2020
Sep 30, 2019
($13.45M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($54.56M)
Aug 10, 2020